BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

891 related articles for article (PubMed ID: 24355485)

  • 1. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Garcia C; Lyon L; Conell C; Littell RD; Powell CB
    Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
    Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
    Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
    Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis.
    Escobar PF; Starks DC; Fader AN; Barber M; Rojas-Espalliat L
    Gynecol Oncol; 2010 Oct; 119(1):43-7. PubMed ID: 20579712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
    Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U
    BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
    Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Kim-Sing C; Ghadirian P; Sun P; Narod SA
    Clin Genet; 2014 Jan; 85(1):21-30. PubMed ID: 23859469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
    Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
    Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.